NO20043313L - Anvendelse av COX-2 inhibitorer i kombinasjon med antivirale midler for behandling av Papilloma virus infeksjoner - Google Patents

Anvendelse av COX-2 inhibitorer i kombinasjon med antivirale midler for behandling av Papilloma virus infeksjoner

Info

Publication number
NO20043313L
NO20043313L NO20043313A NO20043313A NO20043313L NO 20043313 L NO20043313 L NO 20043313L NO 20043313 A NO20043313 A NO 20043313A NO 20043313 A NO20043313 A NO 20043313A NO 20043313 L NO20043313 L NO 20043313L
Authority
NO
Norway
Prior art keywords
cox
inhibitors
treatment
combination
antiviral agents
Prior art date
Application number
NO20043313A
Other languages
English (en)
Norwegian (no)
Inventor
Kong Teck Chong
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20043313L publication Critical patent/NO20043313L/no
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82BNANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • HELECTRICITY
    • H01ELECTRIC ELEMENTS
    • H01LSEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/02Manufacture or treatment of semiconductor devices or of parts thereof
    • H01L21/027Making masks on semiconductor bodies for further photolithographic processing not provided for in group H01L21/18 or H01L21/34

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Computer Hardware Design (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Power Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20043313A 2002-01-10 2004-11-04 Anvendelse av COX-2 inhibitorer i kombinasjon med antivirale midler for behandling av Papilloma virus infeksjoner NO20043313L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34755002P 2002-01-10 2002-01-10
PCT/US2003/000016 WO2003059347A1 (en) 2002-01-10 2003-01-10 Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections

Publications (1)

Publication Number Publication Date
NO20043313L true NO20043313L (no) 2004-10-08

Family

ID=23364195

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043313A NO20043313L (no) 2002-01-10 2004-11-04 Anvendelse av COX-2 inhibitorer i kombinasjon med antivirale midler for behandling av Papilloma virus infeksjoner

Country Status (16)

Country Link
US (1) US20030211163A1 (es)
EP (1) EP1463500A1 (es)
JP (1) JP2005519061A (es)
KR (1) KR20040072720A (es)
CN (1) CN1697654A (es)
AU (1) AU2003201811A1 (es)
BR (1) BR0306820A (es)
CA (1) CA2472459A1 (es)
CO (1) CO5590913A2 (es)
IL (1) IL162726A0 (es)
MX (1) MXPA04006572A (es)
NO (1) NO20043313L (es)
PL (1) PL371252A1 (es)
RU (1) RU2004121147A (es)
WO (1) WO2003059347A1 (es)
ZA (1) ZA200404881B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
EP1700918B1 (en) 1999-08-25 2014-01-15 Allergan, Inc. Activatable recombinant neurotoxins
US20040152752A1 (en) * 2002-05-30 2004-08-05 Chong Kong Teck Treatment for human papillomavirus
EP1572186A2 (en) * 2002-12-19 2005-09-14 Pharmacia Corporation Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents
WO2005055932A2 (en) 2003-12-02 2005-06-23 3M Innovative Properties Company Therapeutic combinations and methods including irm compounds
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US8080560B2 (en) 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
PE20061303A1 (es) * 2005-03-30 2006-12-07 Astion Dev As Composicion farmaceutica que comprende oxaprozina
CA2609303A1 (en) * 2005-05-18 2006-11-23 Alt Solutions, Inc. Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer
KR100644968B1 (ko) * 2005-10-28 2006-11-14 한국과학기술연구원 생체적합성 실리콘 나노입자의 제조 방법
JP2010504359A (ja) 2006-09-20 2010-02-12 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 局部麻酔および/または疼痛緩和のための、揮発性麻酔剤を送達するための方法
ITRM20080027A1 (it) * 2008-01-18 2009-07-19 Maria Balestrieri Uso di aciclovir per il trattamento delle condilomatosi.
CN102014961B (zh) 2008-01-22 2017-10-13 得克萨斯大学体系董事会 用于局部麻醉和/或疼痛缓解的含有萃取溶剂的挥发性麻醉剂组合物
BRPI0910891A2 (pt) * 2008-04-15 2015-09-29 Mallinckrodt Inc composições contendo compostos antivirais e métodos de usar os mesmo
IL192335A0 (en) * 2008-06-19 2011-08-01 Avivi Easy Life Ltd Antiviral compounds
US20110218241A1 (en) * 2010-03-06 2011-09-08 Cacao Bio-Technologies, Llc Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts
JP2012020991A (ja) * 2010-06-16 2012-02-02 Takasago Internatl Corp 経皮吸収促進剤、及びこれを含有する皮膚外用製剤
US10632087B2 (en) 2012-02-06 2020-04-28 Innovative Med Concepts, LLC. Famciclovir and meloxicam combination therapy for functional somatic syndromes
TWI646091B (zh) * 2012-12-28 2019-01-01 日商衛斯克慧特股份有限公司 鹽類及晶形
WO2016036588A1 (en) * 2014-09-03 2016-03-10 Merck Sharp & Dohme Corp. Pharmaceutical suspensions containing etoricoxib
CN105906496A (zh) * 2016-05-16 2016-08-31 苏州毕诺佳医药技术有限公司 一种阿昔洛韦的药物组合物及其医药用途
CN117860740A (zh) * 2020-12-28 2024-04-12 中以海德人工智能药物研发股份有限公司 一种用于治疗或预防病毒性肝炎的药物组合物及其应用
WO2022245950A1 (en) * 2021-05-19 2022-11-24 University Of Miami Treatment of infections in and around the eye

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6180651B1 (en) * 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
CN1098256C (zh) * 1996-04-12 2003-01-08 G·D·瑟尔公司 作为cox-2抑制剂前药的取代的苯磺酰胺衍生物
GB9615867D0 (en) * 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
WO1999030721A1 (en) * 1997-12-17 1999-06-24 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
KR20020024587A (ko) * 1999-05-14 2002-03-30 린다 에스. 스티븐슨 염증 매개성 감염에 대한 항염증 치료
US20030004142A1 (en) * 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway
WO2002085327A2 (en) * 2001-04-18 2002-10-31 Oraltech Pharmaceuticals, Inc. Use of nsaids for prevention and treatment of cellular abnormalities of the female reproductive tract

Also Published As

Publication number Publication date
RU2004121147A (ru) 2005-04-10
KR20040072720A (ko) 2004-08-18
IL162726A0 (en) 2005-11-20
PL371252A1 (en) 2005-06-13
US20030211163A1 (en) 2003-11-13
CO5590913A2 (es) 2005-12-30
JP2005519061A (ja) 2005-06-30
ZA200404881B (en) 2005-08-31
MXPA04006572A (es) 2005-11-04
BR0306820A (pt) 2004-12-07
CN1697654A (zh) 2005-11-16
CA2472459A1 (en) 2003-07-24
AU2003201811A1 (en) 2003-07-30
WO2003059347A1 (en) 2003-07-24
EP1463500A1 (en) 2004-10-06

Similar Documents

Publication Publication Date Title
NO20043313L (no) Anvendelse av COX-2 inhibitorer i kombinasjon med antivirale midler for behandling av Papilloma virus infeksjoner
DK1894564T3 (da) Anvendelse af en IBAT inhibitor til behandling eller profylakse af konstipation
EE05516B1 (et) Indasoolid bensotiasoolid ja bensoisotiasoolid nende valmistamine ning kasutamine
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
CY2013043I1 (el) Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv
CY2014031I1 (el) Τροποποιημενα 2’ και 3’-νουκλεοζιτικα προφαρμακα για θεραπεια μολυνσεων απο flaviviridae
DK1554518T3 (da) Gevindskåret rör med overfladebehandling
NO20053782D0 (no) Behandling av kreft med 2-deoksyglukose
PL376454A1 (en) 1-acyl-pyrrolidine derivatives for the treatment of viral infections
FI20021144A (fi) Menetelmä suuntaajasiltojen yhteydessä
EP1765330A4 (en) PYRANOINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DISEASE OR INFECTION CAUSED BY HEPATITIS C VIRUS
DK1487828T3 (da) Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
FR2864552B1 (fr) Traitement de surface par hydroxysulfate
EE200300473A (et) Tsüano-asendatud dihüdropürimidiinühendid ja nende kasutamine haiguste raviks
EE200300474A (et) Tsüano-asendatud dihüdropürimidiinühendid ja nende kasutamine haiguste raviks
NO20041024D0 (no) Anvendelse av BIBN4096 i kombinasjon med andre antimigrenelegemidler for behandling av migrene
FI20010557A0 (fi) Menetelmä vaihtosuuntaajan yhteydessä
DE60326190D1 (de) des Körpers
PL377427A1 (pl) Sposoby i kompozycje do leczenia infekcji wirusem opryszczki z zastosowaniem inhibitorów selektywnych względem cyklooksygenazy-2 lub inhibitorów cyklooksygenazy-2 w połączeniu ze środkami przeciwwirusowymi
DE602004021477D1 (de) Kondensierte heterocyclen und deren verwendungen
DK1545553T3 (da) Anvendelse af alkylphosphocholiner i kombination med antitumormedikamenter
DK1565064T3 (da) Coatingindretning med integreret rengöringsindretning
DK1496918T3 (da) Anvendelse af natriummetaarsenit til behandling af tumorer
DK1461042T3 (da) Anvendelse af desoxypeganin til behandling af klinisk depression
NO20025303L (no) Anvendelse av substituerte akryloyl-distamycin-derivater i behandlingen avtumorer assosiert med höye nivåer av glutation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application